Ulcerative colitis market seen reaching $17.82 billion by 2035

Market Research Future projects the global ulcerative colitis market will grow from $11.81 billion in 2026 to $17.82 billion by 2035, driven by rising IBD incidence, broader use of oral advanced therapies and biosimilar savings. The outlook points to faster diagnosis, wider insurance coverage and a shift toward home-based treatment channels across major regions.

Why it matters: - The ulcerative colitis market is expanding as more patients are diagnosed and treated earlier, pushing long-term demand for biologics, oral small molecules and other advanced therapies. - The market’s growth matters for payers, drugmakers and health systems because access, reimbursement and delivery models are shifting at the same time. - Market Research Future projects the market will rise from $11.81 billion in 2026 to $17.82 billion by 2035, a 4.68% CAGR.

What happened: - Market Research Future published a forecast for the global ulcerative colitis market on June 16, 2026. - The report estimates the market at $11.28 billion in 2025. - The report forecasts growth through 2035, with the market reaching $17.82 billion. - The forecast is tied to rising global inflammatory bowel disease incidence, class expansion in JAK inhibitors and S1P receptor modulators, and biosimilar-driven budget reallocation. - The company offers a free sample and customization requests for the report.

The details: - The report says global IBD therapy demand in newly industrialized nations has increased 35% in age-standardized terms since 2010, based on the Global Burden of Disease Study 2024. - UC prevalence now exceeds 500 per 100,000 in parts of Northern Europe. - Incidence in China’s eastern provinces now rivals Western rates seen two decades ago. - Early diagnosis is expanding the treated population and increasing prescription volume. - Treat-to-target care is pushing treatment escalation based on endoscopic and histologic endpoints, not symptoms alone. - That shift favors therapies with mucosal healing data and supports adoption of IL-23 inhibitors. - Subcutaneous self-injection is moving biologic distribution away from infusion centers and into home-based care. - JAK inhibitors and S1P receptor modulators are widening the oral advanced therapy category. - Tofacitinib, upadacitinib and filgotinib are cited as major JAK therapies. - Ozanimod and etrasimod are adding oral competition in the S1P class. - The report says oral agents can control symptoms within about two weeks, versus 8 to 14 weeks for biologic onset. - The FDA’s 2024 label update removing boxed warnings from select JAK agents improved prescriber confidence, according to the report. - Real-world registry data cited in the report show 60-day clinical remission rates above 45% in moderate-to-severe patients. - The European biosimilar market for adalimumab and infliximab generated an estimated $4.2 billion in savings from 2018 to 2024 across all indications. - The report says anti-TNF pricing fell 30% to 45% in competitive markets, freeing payer budgets for newer agents. - Risankizumab and mirikizumab have helped establish IL-23 drugs as a core option for refractory disease. - Phase III data cited in the report show mucosal healing above 35% at one year. - AbbVie reported $1.9 billion in combined IBD revenue from risankizumab in its 2024 annual filing, according to the report. - The VEGA trial showed endoscopic improvement of 49.1% with dual biologic induction using guselkumab plus golimumab, the report says. - Anti-TNF biologics held about 40.5% of revenue in 2025. - JAK inhibitors are projected to be the fastest-growing drug class at 14.72% CAGR from 2026 to 2035. - Pancolitis held about 32.2% of disease-type share in 2025. - Fulminant colitis is projected to grow at 9.05% CAGR over the forecast period. - Parenteral administration held about 70.2% of revenue in 2025. - Oral therapies accounted for $3.28 billion in 2025. - Rectal therapies are projected to grow at 8.73% CAGR. - Hospital pharmacies held about 45.7% of distribution-channel share in 2025. - Online pharmacies are projected to grow at 9.45% CAGR.

Between the lines: - The market is moving from symptom control toward deeper remission goals, which tends to favor higher-value specialty drugs. - Biosimilar savings are not shrinking the market so much as reshaping it, with payer budgets shifting from older anti-TNFs to premium next-generation agents. - The report points to a broader shift away from infusion-center dependence and toward home-based and oral treatment models. - Regional policy changes, especially in the U.S. and China, are acting as demand accelerators by reducing patient cost barriers. - The competitive field is still concentrated, but the report describes growing fragmentation in biosimilars and more competition among newer mechanisms of action.

What's next: - The report expects Asia-Pacific to be the fastest-growing region through 2035 at 7.76% CAGR. - China is projected to grow at 8.35% CAGR, supported by NRDL additions and lower infliximab prices from centralized procurement. - The U.S. market remains dominant in North America, with biologic spending averaging $35,000 to $55,000 per patient annually. - Europe is expected to keep expanding on country-specific reimbursement and access policies. - The report says oral biologic formulations could emerge around 2030 to 2032 if permeation-enhancing nanotechnology succeeds. - AI-driven treatment selection and biomarker-guided therapy could reduce treatment cycling costs by 20% to 30% in the early 2030s. - The report says machine learning models trained on records from more than 500,000 UC patients can predict biologic response with 78% accuracy before treatment starts.

The bottom line: - Ulcerative colitis is becoming a more crowded, more accessible and more innovation-driven market, with growth powered by diagnosis expansion, oral drug adoption and payer-led shifts in where care is delivered.